Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

curcumine anticancer 690x350

News and Trends 26 Nov 2014

The Highest Ever Bioavailable Curcumin is Coming in Europe

Theravalues Corporation, Tokyo based company, will launch Theracurmin® Super for the European market at Hi Europe 2014, an event which will take place in Amsterdam at the beggining of December. Curcumin is a turmeric derivative, which is the pigment that gives its yellow-orange color to curry. It is a compound that has been the subject of many studies, […]

November 26, 2014 - 2 minutesmins - By Julie Lellouche

promethera

News and Trends 25 Nov 2014

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, raised 25,33 million euros. The major innovation of Promethera HepaStem is based on Heterologous Human Adult Liver Progenitor Cells (HHALPC). It is a potential to treat a wide variety of congenital […]

November 25, 2014 - 2 minutesmins - By Julie Lellouche

actavis allergan

News and Trends 24 Nov 2014

Will New Actavis-Allergan Entity Lead to Be in the World Top 10 Drugmakers Companies?

The US pharmaceutical company Allergan, known for their Botox, agreed an Actavis bid of 53 billion euros, they permanently passed up the proposition of Valeant Pharmaceuticals International and the activist investor William Ackman. The Allergan-Actavis entity will have a diversified portfolio of medicines and generic, especially in dermatology, gynecology and ophthalmology. It should generate about […]

November 24, 2014 - 2 minutesmins - By Julie Lellouche

Munich

News and Trends 23 Nov 2014

Munich: Why is it One of the Best Biotech Cluster in Europe ?

The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich’s status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study carried out by the City of Munich, the IHK and BioM based […]

November 23, 2014 - 3 minutesmins - By Julie Lellouche

Merck Pfizer

News and Trends 22 Nov 2014

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents to fight cancer. Now, the last Pfizer’s proposal to AstraZeneca is pending. Merck will get an upfront payment of €682 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible […]

November 22, 2014 - 2 minutesmins - By Julie Lellouche

Deinocossus Synthetic biology france leading

News and Trends 18 Nov 2014

Is France Leading the European Synthetic Biology-Based Biofuel Field?

France has great Synthetic Biology Biotech companies. Paris-based Global Bioenergies carried out the first isobutene production trial in its industrial pilot of Pomacle-Bazancourt in the east of France. Two other companies, Deinove and Fermentalg are growing extremely fast, and giant Total is investing massively in the field. Is France on the good way to become […]

November 18, 2014 - 3 minutesmins - By Julie Lellouche

ADVERTISEMENT

Intarcia Platform Technology deal Servier

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first device without injection able to deliver the molecule Exenatide during one year. It is a huge step forward in treating type 2 diabetes. Indeed, most people forget […]

November 15, 2014 - 2 minutesmins - By Julie Lellouche

Onxeo Spectrum

News and Trends 14 Nov 2014

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Onxeo, an innovative company specializing in the development of orphan oncology drugs, founded after the merger of BioAlliance Pharma and Topotarget, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq by the FDA. Early July 2014, Beleodaq was granted by the […]

November 14, 2014 - 3 minutesmins - By Joachim Eeckhout

Way to control genes within human brain

News and Trends 14 Nov 2014

A Way to Control Genes within Human Brain?

Researchers at the Department of Biosystems in Basel have developed a novel gene regulation method that enables thought-specific brainwaves to control the conversion of genes into proteins, so the genes expression. It opens new ways to control gene expression within your brain and could lead to brain surgeries. In this new study, bioengineers placed implants inside […]

November 14, 2014 - 2 minutesmins - By Julie Lellouche

BIO Europe

News and Trends 13 Nov 2014

BIO-Europe, “The place to be for partnering in Europe”

The title may seem a bit catchy, but that’s what lot of companies told me during my visit at BIO-Europe 2014 in Francfort. Why is it so? Surely because of the high profile of attendees, attracted by the prestigious brand and the leadership of BIO’s events. To open the cession, Anna Chrisman, Group managing Director of […]

November 13, 2014 - 3 minutesmins - By Joachim Eeckhout

Ziarco Pharma 27 million

News and Trends 11 Nov 2014

Ziarco Pharma raises €27M two years after founding

Ziarco Group Ltd, a British biopharmaceutical start-up focusing on inflammatory skin diseases, bags €27M for Series B financing round. This fast-growing 2 year old company already raised €21.4M in a Serie A lead by Pfizer and is now accelerating even more. This second fundraising will enable clinical Phase II Proof-of-Concept studies for ZPL-389, a histamine H4 receptor antagonist […]

November 11, 2014 - 2 minutesmins - By Julie Lellouche

m 1407852344

News and Trends 8 Nov 2014

First Anti-bacterial Enzyme Against MRSA for Use in Humans

Change the way we fight against bacterial infections: MICREOS launches its first anti-bacterial enzyme for use in humans against MRSA (Methicillin-resistant Staphylococcus aureus). Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA). Emergence of […]

November 8, 2014 - 3 minutesmins - By Cédric Brock

ADVERTISEMENT